Semin Thromb Hemost November 2020 PMID 33080636

Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.

Jonathan Douxfils, Laure Morimont, Céline Bouvy

Mentions

4
Peak: 1 in May 2021
across 2 sources since May 2021

Extended reach

2,347
potential audience

Total likes

21

Video views

1,632

Mentions per month

May 2021 – Mar 2024

Where it's discussed

  • YouTube3 videos
  • X / Twitter1 posts

AI synopsis

What people are saying

The discussions reflect curiosity and support, with users expressing the importance of better testing for blood clot risks, as seen in comments about genetic factors and the need for ongoing monitoring. Words like 'important' and questions about 'how to improve testing' indicate thoughtful engagement and recognition of the article's potential significance.

AgreementModerate agreement

Most discussions acknowledge the importance of the article, especially emphasizing the potential for improved testing methods and personalized risk assessment.

InterestHigh interest

The topic attracts high interest from users discussing personalized medicine and the relevance of genetic screening.

EngagementModerate engagement

Posts include personal opinions and questions, showing moderate engagement with some depth, such as questioning the feasibility of current testing methods.

ImpactModerate impact

Discussions imply the article could influence future research directions and testing protocols, suggesting a moderate to high impact.

Abstract in brief

  • Oral contraceptives (COCs) impact blood clotting by increasing procoagulant factors and decreasing anticoagulant factors, especially with newer generations of pills, which boosts the risk of blood clots.
  • The risk of venous thromboembolism (VTE) from COCs is higher when combined with other genetic or environmental risk factors, making testing important not only before starting COCs but also during use to monitor clot risk.
  • Genetic factors like factor V Leiden and mutations in blood group or specific genes are linked to higher VTE risk, but current genetic screening cannot fully predict who will develop blood clots; tests like the endogenous thrombin potential-based activated protein C resistance are being explored to better assess thrombogenicity.]

Top posts

Most liked on X and Bluesky
все люди бобры
@aligatorsha13 · X

@doctormongol @Ysterikus @regenzeit2 @ariarzer а вас в гугле забанили, да? и пабмедом не умеете пользоваться тоже? там вагон исследований за 20+ лет https://t.co/vRJWUGl450

Mar 23, 2024 · 6 likes · 716 followers View post →

All mentions

все люди бобры
@aligatorsha13 · X

@doctormongol @Ysterikus @regenzeit2 @ariarzer а вас в гугле забанили, да? и пабмедом не умеете пользоваться тоже? там вагон исследований за 20+ лет https://t.co/vRJWUGl450

Mar 23, 2024 · 6 likes · 716 followers View post →